

Financial Highlights

		FY2011	FY2012	FY2013	FY2014 (Apr-Dec) Standardizing the Company's business year	FY2015	FY2015 1Q (Jan-Mar)	FY2016 1Q (Jan-Mar)	Estimate FY2016 (Jan-Jun)	Estimate FY2016 (Jan-Dec)
Net sales	(Billions of yen)	1,154.6	1,218.1	1,452.8	1,224.3	1,445.2	385.1	282.6	608.0	1,250.0
	YoY	2.4%	5.5%	19.3%	7.9%	-8.1%		-26.6%		
Operating income	(Billions of yen)	148.7	169.7	198.7	196.5	151.8	51.6	26.8	25.0	70.0
	YoY	17.7%	14.1%	17.1%	7.4%	-29.0%		-48.1%		
Ordinary income	(Billions of yen)	152.1	184.5	215.2	217.2	159.9	51.5	27.3	30.0	80.0
	YoY	18.5%	21.3%	16.7%	8.9%	-32.2%		-47.0%		
Net income	(Billions of yen)	92.2	122.4	151.0	143.1	84.1	34.0	18.6	20.0	50.0
	YoY	11.9%	32.8%	23.3%	2.7%	-45.8%		-45.1%		
R&D expenses	(Billions of yen)	159.2	192.4	249.0	172.9	201.0	44.7	36.0	92.0	185.0
	YoY	-3.3%	20.8%	29.4%	4.6%	-19.5%		-19.4%		
Overseas net sales	(Billions of yen)	579.7	622.7	824.4	757.0	805.8	248.8	140.9	298.0	593.0
	% of net sales	50.2%	51.1%	56.8%	61.8%	55.8%		49.9%	49.0%	47.4%

(Yen)

Exchange rate (Yen)	FY2011	FY2012	FY2013	FY2014 (Apr-Dec) Standardizing the Company's business year	FY2015	FY2015 1Q (Jan-Mar)	FY2016 1Q (Jan-Mar)	FY2016
US\$	79.79	79.80	97.72	106.72	121.10	119.15	115.35	120.00
Euro	111.12	102.55	129.77	140.20	134.30	133.99	127.14	135.00

(Billions of yen)

Selling, general and administrative expenses	FY2011	FY2012	FY2013	FY2014 (Apr-Dec) Standardizing the Company's business year	FY2015	FY2015 1Q (Jan-Mar)	FY2016 1Q (Jan-Mar)	Estimate FY2016 (Jan-Jun)	Estimate FY2016 (Jan-Dec)
Selling, general and administrative expenses	616.6	654.6	812.4	681.5	844.1	223.9	161.5	373.0	745.0
(% of net sales)	53.4%	53.7%	55.9%	55.7%	58.4%	58.2%	57.1%	61.3%	59.6%
Promotion expenses	174.4	156.2	192.0	188.0	195.6	73.0	24.7		
Personnel expenses	99.8	103.7	124.0	97.9	152.5	37.2	37.5		
Advertising expenses	25.1	29.5	34.2	26.0	33.3	6.0	7.7		
R&D expenses	159.2	192.4	249.0	172.9	201.0	44.7	36.0	92.0	185.0
(% of net sales)	13.8%	15.8%	17.1%	14.1%	13.9%	11.6%	12.7%	15.1%	14.8%
R&D expenses of pharmaceutical business	149.3	183.5	240.8	166.1	191.4	42.3	33.9	87.0	175.0

(Billions of yen)

Capital expenditures	FY2011	FY2012	FY2013	FY2014 (Apr-Dec) Standardizing the Company's business year	FY2015	FY2015 1Q (Jan-Mar)	FY2016 1Q (Jan-Mar)	Estimate FY2016 (Jan-Jun)	Estimate FY2016 (Jan-Dec)
Capital expenditures	43.3	63.3	179.0	88.2	523.9	400.9	18.6	25.0	50.0

(Billions of yen)

Depreciation	FY2011	FY2012	FY2013	FY2014 (Apr-Dec) Standardizing the Company's business year	FY2015	FY2015 1Q (Jan-Mar)	FY2016 1Q (Jan-Mar)	Estimate FY2016 (Jan-Jun)	Estimate FY2016 (Jan-Dec)
Depreciation	48.1	45.5	49.8	45.5	71.4	18.3	17.4	35.0	70.0

Sales to Customers by Market

(Billions of yen)

Net sales by business segment	FY2011	FY2012	FY2013	FY2014 (Apr-Dec) Standardizing the Company's business year	FY2015	FY2015 1Q (Jan-Mar)	FY2016 1Q (Jan-Mar)	Change
Consolidated sales	1,154.6	1,218.1	1,452.8	1,224.3	1,445.2	385.1	282.6	-26.6%
Pharmaceutical business	782.2	850.9	1,035.1	883.5	971.8	288.7	181.7	-37.0%
Japan	326.5	351.8	372.9	273.7	386.1	85.0	90.3	6.2%
North America	361.1	389.0	530.5	481.6	368.0	152.5	54.4	-64.3%
Others	94.7	110.0	131.7	128.3	217.7	51.1	37.0	-27.6%
Nutraceutical business	251.3	246.9	281.1	232.7	321.6	61.7	66.3	7.6%
Japan	147.4	142.3	147.5	109.8	141.0	25.6	26.7	4.4%
North America	45.8	49.8	59.8	55.8	86.0	15.3	17.2	12.7%
Others	58.1	54.8	73.9	67.1	94.6	20.8	22.4	7.8%
Consumer products business	48.0	45.2	43.8	34.4	42.9	9.0	8.9	-1.8%
Japan	42.0	39.2	36.6	27.9	32.7	6.7	6.5	-2.6%
North America	5.4	5.4	6.9	6.1	9.7	2.3	2.4	3.4%
Others	0.6	0.6	0.3	0.3	0.5	0.1	0.0	-70.8%
Other business	73.1	75.0	92.8	73.7	109.0	25.7	25.6	-0.4%
Japan	59.1	62.0	71.4	55.9	79.7	18.9	18.1	-4.4%
North America	1.3	1.4	2.3	1.8	1.9	0.4	0.7	58.2%
Others	12.7	11.6	19.0	16.0	27.4	6.3	6.8	7.4%
Japan -total	574.9	595.3	628.3	467.3	639.5	136.3	141.7	4.0%
North America - total	413.5	445.7	599.6	545.3	465.6	170.6	74.7	-56.2%
Others - total	166.2	177.1	224.9	211.7	341.2	78.3	66.2	-15.4%
Overseas net sales	579.7	622.7	824.4	757.0	806.8	248.8	140.9	-43.4%
Overseas net sales ratio	50.2%	51.1%	56.8%	61.8%	55.8%	64.6%	49.9%	

Net Sales and Operating Income by Geographical and Business Segment

(1) Geographical segment

(Billions of yen)

	FY2011	FY2012	FY2013	FY2014 (Apr-Dec) Standardizing the Company's business year	FY2015	FY2015 1Q (Jan-Mar)	FY2016 1Q (Jan-Mar)	Change
Net sales	1,154.6	1,218.1	1,452.8	1,224.3	1,445.2	385.1	282.6	-26.6%
Japan*	779.1	842.5	982.1	738.2	835.5	185.4	174.3	-6.0%
North America*	437.5	474.1	652.1	601.9	542.1	186.7	91.6	-50.9%
Others*	142.4	138.2	204.4	189.6	259.1	64.5	60.1	-6.9%
Eliminations/corporate	-204.4	-236.7	-385.9	-305.4	-191.5	-51.5	-43.4	

*Intersegment sales are included.

(Billions of yen)

	FY2011	FY2012	FY2013	FY2014 (Apr-Dec) Standardizing the Company's business year	FY2015	FY2015 1Q (Jan-Mar)	FY2016 1Q (Jan-Mar)	Change
Operating income	148.7	169.7	198.7	196.5	151.8	51.6	26.8	-48.1%
Japan	142.5	160.8	217.5	156.2	98.8	22.6	22.4	-1.2%
North America	14.4	16.2	-5.0	12.8	-11.2	0.3	3.8	1021.9%
Others	3.7	6.4	1.9	16.8	27.4	10.4	6.2	-40.0%
Eliminations/corporate	-12.0	-13.8	-15.7	10.7	36.8	18.2	-5.7	

(2) Business segment

(Billions of yen)

	FY2011	FY2012	FY2013	FY2014 (Apr-Dec) Standardizing the Company's business year	FY2015	FY2015 1Q (Jan-Mar)	FY2016 1Q (Jan-Mar)	Change
Net sales	1,154.6	1,218.1	1,452.8	1,224.3	1,445.2	385.1	282.6	-26.6%
Pharmaceutical business*	782.2	850.9	1,035.1	883.5	971.8	288.7	181.7	-37.0%
Nutraceutical business*	254.8	251.8	287.1	238.2	330.2	63.6	68.8	8.3%
Consumer products business*	49.2	46.9	43.9	34.5	43.2	9.2	9.0	-2.2%
Other business*	108.6	111.7	130.3	102.2	145.2	34.1	33.6	-1.3%
Eliminations/corporate	-40.3	-43.1	-43.7	-34.2	-45.2	-10.4	-10.6	

*Intersegment sales are included.

(Billions of yen)

	FY2011	FY2012	FY2013	FY2014 (Apr-Dec) Standardizing the Company's business year	FY2015	FY2015 1Q (Jan-Mar)	FY2016 1Q (Jan-Mar)	Change
Operating income	148.7	169.7	198.7	196.5	151.8	51.6	26.8	-48.1%
Pharmaceutical business	168.5	187.9	212.8	204.8	156.8	60.6	28.8	-52.5%
Nutraceutical business	22.1	21.4	25.4	21.9	31.3	0.4	5.6	1173.0%
Consumer products business	-2.3	-2.4	-2.2	-1.4	-3.3	-0.7	-0.2	-
Other business	1.9	3.9	7.2	5.5	5.9	1.3	1.5	14.1%
Eliminations/corporate	-41.6	-41.0	-44.5	-34.3	-38.8	-10.1	-8.9	

【Pharmaceutical business】

(Billions of yen)

Product name	Company	FY2011	FY2012	FY2013	FY2014 (Apr-Dec) Standardizing the Company's business year	FY2015	FY2015 1Q (Jan-Mar)	FY2016 1Q (Jan-Mar)	Change	Estimate FY2016 (Jan-Mar)	Estimate FY2016 (Jan-Dec)
Antipsychotic agent ABILIFY	Otsuka Pharmaceutical	411.6	438.5	575.7	507.4	347.5	155.5	34.0	-78.1%	60.0	101.0
US		316.1	336.1	455.5	416.5	242.1	125.7	12.7	-89.9%	23.0	29.5
<US\$ million>		<3,960>	<4,208>	<4,659>	<3,900>	<1,999>	<1,055>	<110>	-89.6%	<190>	<245>
Japan		24.8	28.6	34.4	23.7	35.6	7.9	7.6	-3.7%	17.0	36.0
Others		70.7	73.9	85.8	67.2	69.7	21.8	13.8	-36.9%	20.0	35.5
Aripiprazole long acting injection Abilify Maintena	Otsuka Pharmaceutical			4.3	14.4	40.4	7.9	13.4	69.5%	30.0	67.0
US				4.3	13.0	29.9	6.5	9.0	39.3%	20.0	42.5
Japan						1.3	-	0.8		2.5	7.0
Others					1.4	9.2	1.4	3.6	153.9%	7.5	17.5
Antipsychotic agent REXULTI	Otsuka Pharmaceutical					4.6	-	4.4		10.5	28.5
Agent for pseudobablar affect (PBA) NUDEXTA	Otsuka Pharmaceutical					19.2	3.7	5.6	51.8%	12.0	27.0
Anti-platelet agent Pletal/Pletal	Otsuka Pharmaceutical	50.3	45.8	44.2	26.2	31.4	7.7	6.2	-20.3%	13.0	25.5
Japan		44.1	40.1	36.8	20.7	23.3	5.8	4.2	-26.8%	9.0	17.5
Others		6.2	5.7	7.4	5.5	8.2	2.0	1.9	-1.3%	4.0	8.0
Anti-gastritis and anti-gastric ulcer agent Mucosta	Otsuka Pharmaceutical	28.7	23.0	22.0	12.9	15.8	4.1	3.5	-14.8%	6.5	13.0
Japan		26.0	20.5	18.8	10.1	11.4	2.9	2.3	-21.5%	4.5	8.0
Others		2.7	2.5	3.1	2.7	4.4	1.2	1.2	1.9%	2.0	5.0
Anti-metabolite TS-1	Taiho Pharmaceutical	36.5	37.0	37.4	24.0	29.3	6.8	6.6	-3.3%	12.5	23.5
Anti-metabolite UFT	Taiho Pharmaceutical	12.9	11.2	9.5	6.3	7.5	1.7	1.4	-16.1%	3.0	6.0
Reduced folic acid formulation Uzel	Taiho Pharmaceutical	12.7	13.2	11.9	7.9	10.5	2.4	2.3	-7.1%	5.0	10.0
Anticancer LONSURF	Taiho Pharmaceutical				2.3	9.4	0.6	7.8	1134.2%	9.0	20.5
5-HT ₃ receptor antagonist Aloxi	Taiho Pharmaceutical	7.9	10.0	11.0	8.8	12.9	2.7	3.2	17.3%	6.3	13.2
Anticancer Abraxane	Taiho Pharmaceutical	3.2	3.7	8.8	8.2	20.6	3.6	5.0	36.2%	10.0	21.0
Antiepileptic E Keppra	Otsuka Pharmaceutical	4.8	10.5	15.8	13.2	23.3	4.4	6.3	42.9%	12.0	26.0
V ₂ receptor antagonist Samsca/ JINARC	Otsuka Pharmaceutical	6.7	12.8	21.0	20.8	41.6	8.4	11.4	35.3%	21.0	45.5
Japan		1.0	4.2	10.0	12.4	25.7	4.9	6.9	41.3%	12.0	25.0
US		4.9	7.5	9.3	6.0	11.8	2.7	3.1	17.3%	6.0	13.0
Others (including Jinarc)		0.7	1.0	1.7	2.4	4.1	0.8	1.3	57.3%	3.0	7.5
Mucin-production enhancing agent Mucosta Ophthalmic Suspension	Otsuka Pharmaceutical	0.1	1.0	2.9	2.8	4.5	1.1	1.2	7.3%	2.5	5.5
Parkinson's Disease, RLS* treatment Neupro Patch	Otsuka Pharmaceutical		0.2	2.6	4.7	8.3	1.6	2.2	33.3%	5.0	10.5
Anticancer Sprycel (collaboration with BMS)	Otsuka Pharmaceutical	7.6	12.0	26.1	22.9	31.2	6.7	6.7	-0.1%	15.0	32.0
Antibiotic Zosyn/Tazocin (bulk supply)	Otsuka Pharmaceutical	10.7	12.4	14.5	11.8	13.4	1.9	2.6	34.4%	5.0	10.5
Diagnostics -total	Otsuka Pharmaceutical	7.9	8.8	12.6	8.5	12.2	4.0	4.9	22.9%	8.0	14.0
Parenteral nutrition (clinical nutrition) -total		96.0	96.4	103.4	81.5	104.8	23.5	24.5	4.1%	51.0	106.5
Japan	Otsuka Pharmaceutical Factory	88.6	88.8	91.6	68.2	88.2	19.5	19.4	-0.2%	41.0	85.0
Others		7.4	7.6	11.8	13.3	16.6	4.0	5.0	24.8%	10.0	21.5
Pharmaceutical business -total (excluding exports)	Japan	326.5	351.8	372.9	273.7	386.1	85.0	90.3	6.2%	182.0	383.0
Pharmaceutical business -total	Total	782.2	850.9	1,035.1	883.5	971.8	288.7	181.7	-37.0%	368.0	745.0
Milestone and upfront revenue		14.9	41.5	22.0	20.4	66.0	11.6	1.9	-83.8%	13.0	16.0

*RLS : Restless legs syndrome

【Neutraceuticals business】

(10 thousand cases)

Product name	Company	FY2011	FY2012	FY2013	FY2014 (Apr-Dec) Standardizing the Company's business year	FY2015	FY2015 1Q (Jan-Mar)	FY2016 1Q (Jan-Mar)	Change
<i>Pocari Sweat</i> 1 case: 24 bottles, and other (10 thousand cases)	Otsuka Pharmaceutical								
Japan		2,912	2,709	2,860	2,006	2,625	446	480	7.6%
Overseas		1,963	2,151	2,684	2,256	2,608	454	471	3.8%
<i>SOYJOY</i> 1 case: 48 bars (10 thousand cases)	Otsuka Pharmaceutical								
Japan		100	88	109	107	126	24	28	20.7%
Overseas		20	12	16	12	20	5	5	6.1%
<i>Oronamin C</i> 1 case: 50 bottles (10 thousand cases)	Otsuka Pharmaceutical	1,081	1,067	1,105	830	1,025	193	183	-5.6%
<i>Calorie Mate</i> 1 case: 4 bars×30, and other (10 thousand cases)	Otsuka Pharmaceutical	351	335	340	280	381	78	82	4.3%
<i>Tiovita Drink</i> 1 case: 50 bottles (10 thousand cases)	Taiho Pharmaceutical	532	489	402	290	345	64	62	-2.2%
<i>Solmack</i> (10 thousand of bottles)	Taiho Pharmaceutical	1,579	1,588	1,479	1,174	1,501	271	276	1.9%

* Overseas sales include sales of consolidated subsidiaries only.

【Consumer products business】

(10 thousand cases)

Product name	Company	FY2011	FY2012	FY2013	FY2014 (Apr-Dec) Standardizing the Company's business year	FY2015	FY2015 1Q (Jan-Mar)	FY2016 1Q (Jan-Mar)	Change
Bottled Water 1 case: 24 bottles (10 thousand cases)	Otsuka Foods	679	567	580	396	504	78	112	44.6%
Match 1 case: 24 bottles (10 thousand cases)	Otsuka Foods	451	521	514	447	527	91	100	10.2%
Other (tea drinks and other) 1 case: 24 bottles (10 thousand cases)	Otsuka Foods	317	300	265	177	232	47	51	8.8%

【Other business】

(Billions of yen)

Product name	Company	FY2011	FY2012	FY2013	FY2014 (Apr-Dec) Standardizing the Company's business year	FY2015	FY2015 1Q (Jan-Mar)	FY2016 1Q (Jan-Mar)	Change
Functional chemicals	Otsuka Chemical	27.9	26.6	33.5	26.6	34.4	8.8	8.9	1.3%
Fine chemicals	Otsuka Chemical	9.3	10.2	10.1	7.3	10.6	2.9	2.2	-25.7%

Otsuka Group - Pipeline Information

(as of Mar 31, 2016)

Code / <Brand name>	Generic name	Origin	Category	Indication / Dosage form	Country / Region	Development status
Central nervous system, neurological disorders						
OPC-14597 <ABILIFY*>	aripiprazole	Otsuka Pharmaceutical	Dopamine partial agonist	Autism / Oral	JP	Filed
<Abilify Maintena*> Depot injection				Agitation associated with dementia of the Alzheimer's type / Oral	JP	Phase III
				Bipolar I / Depot injection	JP, US, EU	Phase III
L059 <E Keppra>	levetiracetam	UCB	Anti-epileptic drug	Epilepsy (generalized onset seizures) / Oral, Injection	JP	Approved
OPC-34712 <REXULTI*>	brexipiprazole	Otsuka Pharmaceutical	Dopamine partial agonist	Major depressive disorder / Oral	EU	Phase III
				Schizophrenia / Oral	JP, EU	Phase III
				Agitation associated with dementia of the Alzheimer's type / Oral	US, EU	Phase III
				Posttraumatic stress disorder (PTSD) / Oral	US, EU	Phase III
Lu AE58054	idalopirdine	Lundbeck	selective 5-HT ₆ receptor antagonist	Alzheimer's disease / Oral	US, EU	Phase III
ASC-01	aripiprazole, sertraline	Otsuka Pharmaceutical	Dopamine partial agonist/ Selective serotonin reuptake inhibitor	Major depressive disorder / Oral	JP, Asia	Phase III
AVP-923	dextromethorphan, quinidine	Avanir	NMDA receptor antagonist/ Serotonin and Norepinephrine reuptake inhibitor/ Sigma-1 receptor agonist/ Neuronal nicotinic receptor antagonist	Dyskinesia associated with Parkinson's disease / Oral	US	Phase II
AVP-786	deuterium-modified dextromethorphan, quinidine	Avanir	NMDA receptor antagonist/ Serotonin and Norepinephrine reuptake inhibitor/ Sigma-1 receptor agonist/ Neuronal nicotinic receptor antagonist	Major depressive disorder / Oral	US	Phase II
				Agitation associated with dementia of the Alzheimer's type / Oral	US, EU	Phase III
				Residual schizophrenia symptoms/Oral	US	Phase II
AVP-825 <ONZETRA Xsail*>	sumatriptan	Avanir	5-HT _{1B/1D} receptor agonist	Acute migraine / Nasal powder	US	Approved
TAS-205		Taiho Pharmaceutical	PGD synthase-inhibitor	Duchenne Muscular Dystrophy (DMD) / Oral	JP	Phase I
Lu AA36143	nalmeferene	Lundbeck	Opioid receptor antagonist	Lowering alcohol consumption of alcohol dependence / Oral	JP	Phase III
Lu AF20513		Lundbeck	β-amyloid vaccine	Preventing progression of Alzheimer's demetia/injection	EU	Phase I

Note: In general, Otsuka disclose compounds that are in Phase II or later stage of development, although some compounds in Phase I are disclosed in the above table.
*: Product names used outside Japan.

Otsuka Group - Pipeline Information

(as of Mar 31, 2016)

Code / <Brand name>	Generic name	Origin	Category	Indication / Dosage form	Country / Region	Development status
Oncology						
S-1 <TS-1> Japan, Korea <Teyuno> EU	tegafur, gimeracil, oteracil	Taiho Pharmaceutical	Anti-cancer (Anti-metabolite)	Uterocervical cancer / Oral	JP, Asia	Phase III
TAS-102 <LONSURF*>	trifluridine, tipiracil	Taiho Pharmaceutical	Anti-cancer	Colorectal cancer / Oral	EU Asia	Approved** Phase III
				Gastric cancer / Oral	JP, US, EU	Phase III
TAS-118	tegafur, gimeracil, oteracil, folinate	Taiho Pharmaceutical	Anti-cancer (Anti-metabolite)	Pancreatic cancer / Oral	JP, Asia	Phase III
				Gastric cancer / Oral	JP, Asia	Phase III
<SATIVEX*>	nabiximols	GW Pharmaceuticals	Cannabinoid (THC, CBD)	Cancer pain / Oral spray	US	Phase III
SGI-110	guadecitabine	Astex	Anti-cancer	Ovarian cancer / Injection	US, EU	Phase II
				Hepatocellular carcinoma / Injection	US, EU	Phase II
				Acute myeloid leukemia, Myelodysplastic syndrome / Injection	US	Phase II
				Acute myeloid leukemia / Injection	US, EU JP, Asia	Phase III
				Acute myeloid leukemia / Injection	JP	Phase I
AT13387		Astex	Anti-cancer (Molecular-targeted drug)	NSCLC / Injection	US, EU	Phase II
AT7519		Astex	Anti-cancer (Molecular-targeted drug)	Multiple myeloma / Injection	US	Phase II
ASTX727		Astex	Anti-cancer	Myelodysplastic syndrome / Oral	US	Phase II
ASTX660		Astex	Anti-cancer (Molecular-targeted drug)	Solid tumors, Lymphomas/Oral	US	Phase I
OPB-111077		Otsuka Pharmaceutical	Anti-cancer	Solid tumors / Oral	US, Asia	Phase I
OPB-111001		Otsuka Pharmaceutical	Anti-cancer	Solid tumors / Oral	EU	Phase I
TAS-114		Taiho Pharmaceutical	Anti-cancer (Antitumor enhancer)	Solid tumors / Oral	JP, US, EU	Phase I
TAS-115		Taiho Pharmaceutical	Anti-cancer (Molecular-targeted drug)	Solid tumors / Oral	JP	Phase I
TAS-116		Taiho Pharmaceutical	Anti-cancer (Molecular-targeted drug)	Solid tumors / Oral	JP	Phase I
TAS-117		Taiho Pharmaceutical	Anti-cancer (Molecular-targeted drug)	Solid tumors / Oral	JP	Phase I
TAS-119		Taiho Pharmaceutical	Anti-cancer (Molecular-targeted drug)	Solid tumors / Oral	US, EU	Phase I
TAS-120		Taiho Pharmaceutical	Anti-cancer (Molecular-targeted drug)	Solid tumors / Oral	JP, US, EU	Phase I
TAS-121		Taiho Pharmaceutical	Anti-cancer (Molecular-targeted drug)	Solid tumors / Oral	JP	Phase I
TAS3681		Taiho Pharmaceutical	Anti-androgenic agent	Prostate cancer / Oral	US, EU	Phase I
OCV-501		Otsuka Pharmaceutical	WT1 targeted cancer vaccine	Secondary prevention of elderly acute myeloid leukemia / Injection	JP, Asia	Phase II
OCV-C02		OncoTherapy Science	Therapeutic cancer vaccine	Colorectal cancer / Injection	JP	Phase I
OPC-12759	rebamipide	Otsuka Pharmaceutical	Oral mucosal protectant / mucosal healing agent	Stomatitis associated with cancer chemoradiotherapy / Solution	JP	Phase II

Note: In general, Otsuka disclose compounds that are in Phase II or later stage of development, although some compounds in Phase I are disclosed in the above table.

*: Product names used outside Japan.

** : Events after March 31, 2016 TAS-102/Colorectal cancer: approved on April in EU.

Otsuka Group - Pipeline Information

(as of Mar 31, 2016)

Code / <Brand name>	Generic name	Origin	Category	Indication / Dosage form	Country / Region	Development status
Cardiovascular						
OPC-41061 <Samsca [*] / JINARC [*] >	tolvaptan	Otsuka Pharmaceutical	V ₂ receptor antagonist	Hepatic edema / Oral	Asia	Filed
				Autosomal dominant polycystic kidney disease / Oral	US Asia	Phase III Filed
				Cardiac edema / Oral	Asia	Filed
				Carcinomatous edema / Oral	JP	Phase II
				Volume overload in hemodialysis / Oral	JP	Phase II
				Volume overload in peritoneal dialysis / Oral	JP	Phase II
OPC-108459		Otsuka Pharmaceutical		Paroxysmal and persistent atrial fibrillation / Injection	JP, US	Phase I
Other areas						
TAC-202	bilastine	Faes Farma	H ₁ receptor antagonist	Allergic rhinitis / Oral	JP	Filed
				Chronic urticaria, Pruritus associated with skin disease / Oral	JP	Filed
OPC-67683 <Delyba [*] >	delamanid	Otsuka Pharmaceutical	Anti-tuberculosis agent	Multidrug-resistant tuberculosis / Oral	US	Phase III
				Multidrug-resistant tuberculosis for pediatrics / Oral	EU	Phase II
OPC-12759E <Mucosta Ophthalmic Suspension>	rebamipide	Otsuka Pharmaceutical	Mucin-production enhancing agent	Dry eyes / Eye drops MD (Multi Dose)	JP	Phase III
OPF-105	Amino Acid, Carbohydrate, and Fat Emulsion Injection with Electrolytes and Vitamins	Otsuka Pharmaceutical Factory	Protein and amino acid preparation	Peripheral parenteral nutrition solution / Injection	JP	Phase III
OPF-108	Amino Acid and Carbohydrate, and with Electrolytes and Vitamins	Otsuka Pharmaceutical Factory	Protein and amino acid preparation	Total parenteral nutrition / Injection	JP	Filed
ACU-4429	emixustat	Acucela	Visual cycle modulator	Dry AMD / Oral	US	Phase II/III
OPA-6566		Otsuka Pharmaceutical	A _{2a} receptor agonist	Glaucoma / Eye Drops	US	Phase I /II
OPC-1085EL	carteolol, latanoprost	Otsuka Pharmaceutical	β receptor antagonist / PGF _{2α} analogue	Glaucoma / Eye Drops	JP	Filed
OPA-15406		Otsuka Pharmaceutical	PDE4 inhibitor	Atopic Dermatitis / Ointment	US	Phase II
OPS-2071		Otsuka Pharmaceutical	New quinolone based antibacterial agent	Clostridium difficile infection, enteric infection / Oral	JP, Asia	Phase II
Diagnostics						
C13-CAC	Calcium (13C)	Otsuka Pharmaceutical	13C-Calcium Carbonate breath test	For measurement of gastric acidity / In-vivo diagnostic agent	JP	Phase II

Note: In general, Otsuka disclose compounds that are in Phase II or later stage of development, although some compounds in Phase I are disclosed in the above table.

* Product names used outside Japan.

Otsuka Group - Pipeline Information

Changes in Pipeline information Since Dec 2015

Code / <Brand name>	Generic name	Origin	Category	Indication / Dosage form	Country / Region	Development status	Change from 4Q FY2015
---------------------	--------------	--------	----------	--------------------------	------------------	--------------------	-----------------------

Central nervous system, neurological disorders

L059 <E Keppra>	levetiracetam	UCB	Anti-epileptic drug	Epilepsy (generalized onset seizures) / Oral, Injection	JP	Approved	Filed→Approved (Feb 2016)
AVP-825 <ONZETRA Xsail [†] >	sumatriptan	Avanir	5-HT1B/1D receptor agonist	Acute migraine / Nasal powder	US	Approved	Filed→Approved (Jan 2016)

Oncology

TAS-102 <LONSURF [†] >	trifluridine, tipiracil	TaihoPharmaceutical	Anti-cancer	Gastric cancer / Oral	JP, US, EU	Phase III	Added
ASTX727		Astex	Anti-cancer	Myelodysplastic syndrome / Oral	US	Phase II	Phase I → Phase II
TAS3681		Taiho Pharmaceutical	Anti-androgenic agent	Prostate / Oral	US,EU	Phase I	Added

<Events after March 31, 2016>

Code / <Brand name>	Generic name	Origin	Category	Indication / Dosage form	Country / Region	Development status	Change
---------------------	--------------	--------	----------	--------------------------	------------------	--------------------	--------

TAS-102 <LONSURF [†] >	trifluridine, tipiracil	TaihoPharmaceutical	Anti-cancer	Colorectal cancer / Oral	EU	Approved	Filed→Approved (Apr 2016)
---------------------------------	-------------------------	---------------------	-------------	--------------------------	----	----------	---------------------------

<Discontinuation of project development>

Code / <Brand name>	Generic name	Origin	Category	Indication / Dosage form	Country / Region	Development status	
---------------------	--------------	--------	----------	--------------------------	------------------	--------------------	--

OPC-6535	tetomilast	Otsuka Pharmaceutical	Anti-inflammatory agent	COPD / Oral	JP,US, Asia	Phase II	Development Discontinuation
----------	------------	-----------------------	-------------------------	-------------	-------------	----------	-----------------------------

Reason for discontinuation of project development : It could not to move on to phase 3 study due to insufficient scientific evidence from phase 2.

Note: In general, Otsuka disclose compounds that are in Phase II or later stage of development, although some compounds in Phase I are disclosed in the above table.
[†]: Product names used outside Japan.